公开(公告)号：US20240130962A1

公开(公告)日：2024-04-25

申请号：US18351192

申请日：2023-07-11

Applicant: Dyve Biosciences, Inc.

Inventor： Nathan FITZSIMMONS ,  Ryan BEAL ,  Charles A. HARBERT ,  Audrene RICE ,  Brandon SAND ,  Parshva KOTHARY ,  Bruce SAND

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/48 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24

CPC classification number: A61K9/0014 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/4893 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  C12Y304/24069

Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

公开(公告)号：US11964049B2

公开(公告)日：2024-04-23

申请号：US17698896

申请日：2022-03-18

Applicant: Nulixir Inc.

Inventor： Ehsan Moaseri

IPC: A61K9/10 ,  A23L29/10 ,  A23L29/30 ,  A23L33/155 ,  A61K9/00 ,  A61K9/08 ,  A61K9/107 ,  A61K9/16 ,  A61K9/48 ,  A61K9/50 ,  A61K9/51 ,  A61K31/05 ,  A61K31/192 ,  A61K31/198 ,  A61K31/352 ,  A61K31/353 ,  A61K31/375 ,  A61K31/522 ,  A61K31/525 ,  A61K31/593 ,  A61K35/741 ,  A61K36/00 ,  A61K36/06 ,  A61K36/062 ,  A61K36/16 ,  A61K36/185 ,  A61K36/28 ,  A61K36/41 ,  A61K36/53 ,  A61K36/54 ,  A61K36/61 ,  A61K36/67 ,  A61K36/68 ,  A61K47/44 ,  A61K45/06 ,  B82Y5/00

CPC classification number: A61K9/10 ,  A23L29/10 ,  A23L29/30 ,  A23L33/155 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/107 ,  A61K9/1075 ,  A61K9/1652 ,  A61K9/1664 ,  A61K9/167 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K9/4891 ,  A61K9/5042 ,  A61K9/5089 ,  A61K9/513 ,  A61K9/5161 ,  A61K31/05 ,  A61K31/192 ,  A61K31/198 ,  A61K31/352 ,  A61K31/353 ,  A61K31/375 ,  A61K31/522 ,  A61K31/525 ,  A61K31/593 ,  A61K35/741 ,  A61K36/00 ,  A61K36/06 ,  A61K36/062 ,  A61K36/16 ,  A61K36/185 ,  A61K36/28 ,  A61K36/41 ,  A61K36/53 ,  A61K36/54 ,  A61K36/61 ,  A61K36/67 ,  A61K36/68 ,  A61K47/44 ,  A61K45/06 ,  B82Y5/00

Abstract: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

公开(公告)号：US11963947B2

公开(公告)日：2024-04-23

申请号：US17058903

申请日：2019-05-28

Applicant: HUA Medicine (Shanghai) Ltd.

Inventor： Li Chen ,  Yongguo Li ,  Gaosen Wang ,  Huisheng Gao

IPC: A61K31/4155 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/7034 ,  A61K45/06 ,  A61K47/38 ,  A61P3/10 ,  C07D231/38 ,  C07D403/12

CPC classification number: A61K31/4155 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2095 ,  A61K9/2813 ,  A61K9/284 ,  A61K9/2866 ,  A61K31/155 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/7034 ,  A61K45/06 ,  A61K47/38 ,  A61P3/10 ,  C07D231/38 ,  C07D403/12

Abstract: Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.

公开(公告)号：US11957656B2

公开(公告)日：2024-04-16

申请号：US17080180

申请日：2020-10-26

Applicant: The Trustees of Columbia University in the City of New York ,  Levo Therapeutics, Inc.

Inventor： Lisa Cole Burnett ,  Dieter Egli ,  Rudolph L Leibel ,  Sara Cotter

IPC: A61K31/366 ,  A61K31/277 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4162 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/454 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5513 ,  A61K31/69 ,  A61K38/08 ,  A61K38/095 ,  A61K45/06 ,  A61P43/00 ,  A61K38/00

CPC classification number: A61K31/366 ,  A61K31/277 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4162 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/454 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5513 ,  A61K31/69 ,  A61K38/08 ,  A61K38/095 ,  A61K45/06 ,  A61P43/00 ,  A61K38/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/4035 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/4162 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/4375 ,  A61K2300/00 ,  A61K31/44 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/522 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/69 ,  A61K2300/00

Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).

公开(公告)号：US20240115576A1

公开(公告)日：2024-04-11

申请号：US18034142

申请日：2021-10-29

Applicant: OYE Therapeutics, Inc

Inventor： Brett Dines ,  Pamela A. Smith ,  Stephen R. Byrn ,  Susan Bogdanowich-Knipp

IPC: A61K31/522 ,  A61K9/08 ,  A61K31/19 ,  A61K31/198 ,  A61P39/02

CPC classification number: A61K31/522 ,  A61K9/08 ,  A61K31/19 ,  A61K31/198 ,  A61P39/02

Abstract: Compositions comprising, for example, caffeine, sodium benzoate and one or more of lactic acid, acetic acid, aspartic acid and glutamic acid, processes for making the compositions and methods of using the compositions. The methods include accelerating emergence from anesthesia and/or countering the effects of anesthesia, including reversing the effects of anesthesia. The methods also include treating opioid intoxication or overdose.

公开(公告)号：US20240100048A1

公开(公告)日：2024-03-28

申请号：US18532790

申请日：2023-12-07

Applicant: INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Rosa BARREIRA DA SILVA ,  Matthew ALBERT

IPC: A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/001129 ,  A61K45/06 ,  A61P35/00 ,  A61K31/403

Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

公开(公告)号：US20240099976A1

公开(公告)日：2024-03-28

申请号：US18490255

申请日：2023-10-19

Applicant: Sequessome Technology Holdings Limited

Inventor： William HENRY ,  Richard Wolf GARRAWAY

IPC: A61K9/127 ,  A61K8/04 ,  A61K8/14 ,  A61K9/00 ,  A61K9/10 ,  A61K31/155 ,  A61K31/165 ,  A61K31/355 ,  A61K31/522 ,  A61K31/60 ,  A61K31/618 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/24 ,  A61K47/26 ,  A61P17/04 ,  A61P17/10 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08

CPC classification number: A61K9/1272 ,  A61K8/04 ,  A61K8/14 ,  A61K9/0014 ,  A61K9/10 ,  A61K9/127 ,  A61K31/155 ,  A61K31/165 ,  A61K31/355 ,  A61K31/522 ,  A61K31/60 ,  A61K31/618 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/24 ,  A61K47/26 ,  A61P17/04 ,  A61P17/10 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08 ,  A61K33/30

Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

公开(公告)号：US20240091303A1

公开(公告)日：2024-03-21

申请号：US17766492

申请日：2020-10-05

Applicant: Goldfinch Bio, Inc.

Inventor： John Francis Reilly ,  Yossi Dagon ,  Hari Raghu ,  Marie-Francoise Yveline Coeffet-Le Gal ,  Matthew H. Daniels ,  Maolin Yu ,  Mark W. Ledeboer ,  Jean-Christophe P. Harmange ,  Peter H. Mundel

IPC: A61K38/13 ,  A61K31/352 ,  A61K31/4184 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/522 ,  A61P13/12 ,  G01N33/68

CPC classification number: A61K38/13 ,  A61K31/352 ,  A61K31/4184 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/522 ,  A61P13/12 ,  G01N33/6893 ,  G01N2800/52

Abstract: Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I)-(XI), and methods of determining the efficacy of TRPC5 inhibitor therapies using the same.

公开(公告)号：US11931333B1

公开(公告)日：2024-03-19

申请号：US16886730

申请日：2020-05-28

Applicant: Peter Van Horn ,  John M. Guynn

Inventor： Peter Van Horn ,  John M. Guynn

IPC: A61K31/352 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K31/05 ,  A61K31/522 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20 ,  A61K47/44 ,  A61P31/22

CPC classification number: A61K31/352 ,  A61K31/05 ,  A61K31/522 ,  A61K47/10 ,  A61K47/14 ,  A61K47/183 ,  A61K47/20 ,  A61K47/44 ,  A61P31/22 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/06 ,  A61K9/107

Abstract: A topical composition for treating genital herpes includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound. The topical composition may further contain a cannabinoid component, such as CBD, and/or a terpene and/or an essential oil. The topical composition may be in the form of a two-component composition in which a first topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound and the second topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a cannabinoid component.

公开(公告)号：US20240082152A1

公开(公告)日：2024-03-14

申请号：US18519955

申请日：2023-11-27

Applicant: CMPD Licensing, LLC

Inventor： Jay Richard Ray, II

IPC: A61K9/00 ,  A61J3/07 ,  A61K31/135 ,  A61K31/197 ,  A61K31/439 ,  A61K31/522 ,  A61K33/30 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26

CPC classification number: A61K9/0078 ,  A61J3/078 ,  A61K31/135 ,  A61K31/197 ,  A61K31/439 ,  A61K31/522 ,  A61K33/30 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26

Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.